Katherine L. Meyer-Siegler
Research & Development Service
Bay Pines VA Healthcare System
VA Medical Center
Bay Pines
USA
Name/email consistency: high
- Substance P increases cell-surface expression of CD74 (receptor for macrophage migration inhibitory factor): in vivo biotinylation of urothelial cell-surface proteins. Meyer-Siegler, K.L., Xia, S.L., Vera, P.L. Mediators Inflamm. (2009)
- Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Meyer-Siegler, K.L., Vera, P.L., Iczkowski, K.A., Bifulco, C., Lee, A., Gregersen, P.K., Leng, L., Bucala, R. Genes Immun. (2007)
- Macrophage migration inhibitory factor is increased in the urine of patients with urinary tract infection: macrophage migration inhibitory factor-protein complexes in human urine. Meyer-Siegler, K.L., Iczkowski, K.A., Vera, P.L. J. Urol. (2006)
- Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. Meyer-Siegler, K.L., Iczkowski, K.A., Leng, L., Bucala, R., Vera, P.L. J. Immunol. (2006)
- Substance P induced changes in CD74 and CD44 in the rat bladder. Meyer-Siegler, K.L., Vera, P.L. J. Urol. (2005)
- Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. Meyer-Siegler, K.L., Iczkowski, K.A., Vera, P.L. BMC. Cancer (2005)
- Substance P induced release of macrophage migration inhibitory factor from rat bladder epithelium. Meyer-Siegler, K.L., Vera, P.L. J. Urol. (2004)
- Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. Meyer-Siegler, K.L., Leifheit, E.C., Vera, P.L. BMC. Cancer (2004)
- Intraluminal antibodies to macrophage migration inhibitory factor decrease substance P induced inflammatory changes in the rat bladder and prostate. Meyer-Siegler, K.L., Vera, P.L. J. Urol. (2004)